Inmune Bio INMB
NASDAQ INMB
$1.61 +0.01 (+0.62%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inmune Bio (INMB) Long-Term Debt Repayments (2023 - 2024)

Updated

Inmune Bio (INMB) posted Long-Term Debt Repayments of $2.5 million for Q4 2024, unchanged from $2.5 million a year earlier and unchanged from the prior quarter.

Analysis

Inmune Bio (INMB) Long-Term Debt Repayments (2023 - 2024) Analysis & Trends

For FY2024, Inmune Bio's Long-Term Debt Repayments came in at $10 million, up 100.0% from FY2023.

  • In prior years, Inmune Bio's Long-Term Debt Repayments was $5 million in FY2023.
  • According to Business Quant data, Long-Term Debt Repayments for the three prior quarters was $2.5 million (Q3 2024), $2.5 million (Q2 2024) and $2.5 million (Q1 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.00 Mn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 2.00 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 2.46 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 17.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Inmune Bio 42.88 Mn -49.37 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 2.50 Mn
Sep 30, 2024 2.50 Mn
Jun 30, 2024 2.50 Mn
Mar 31, 2024 2.50 Mn
Dec 31, 2023 2.50 Mn
API Access

Inmune Bio Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=INMB&period=max&api_key=YOUR_API_KEY